What is a notable risk when treating with Donepezil?

Donepezil, which is a cholinesterase inhibitor commonly prescribed for the treatment of Alzheimer's disease, can lead to a notable risk of syncope, or fainting. This risk arises because Donepezil can enhance cholinergic activity, potentially resulting in decreased heart rate and subsequent hypotension. In patients, especially those who may already have compromised autonomic regulation due to advanced stages of dementia, this can manifest as syncope.

Additionally, monitoring for signs of syncope is important, particularly in elderly patients who may be more susceptible to these adverse effects. The risk of syncope highlights the need for careful dose adjustment and consideration of overall tolerance to the medication in the context of each patient's specific medical profile. The awareness of this side effect is crucial for caregivers and healthcare providers, as they can take proactive measures to mitigate the risk and associated injuries that may arise from falls or fainting episodes.